AUBERTON-HERVE ANDRE-JACQUES 4
4 · Bionik Laboratories Corp. · Filed Jun 21, 2023
Insider Transaction Report
Form 4
AUBERTON-HERVE ANDRE-JACQUES
Director
Transactions
- Conversion
Common Stock
2023-06-13$0.60/sh+186,111$111,667→ 1,109,271 total(indirect: Shares held through Star SCI) - Purchase
Convertible Promissory Note
2023-06-13$220000.00/sh+1$220,000→ 1 total(indirect: Through Star SCI)Exercise: $0.60Exp: 2024-06-01→ Common Stock, par value $0.001 per share (366,667 underlying)
Holdings
- 95,149
Common Stock
- 10,693(indirect: Shares held through 4A Consulting and Engineering)
Common Stock
Footnotes (2)
- [F1]Effective as of June 13, 2023, approximately $310,185 of principal and accrued interest of a convertible promissory note issued to Star SCI, an affiliate of the reporting person, converted in accordance with its terms into 186,111 shares of the Issuer's common stock
- [F2]The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share.